89 Prevention of rheumatoid arthritis 41 Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, et al. 2020; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 79(6):685–99. 42 Hua C, Buttgereit F, Combe B. 2020; Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 6(1). 43 Strehl C, Ehlers L, Gaber T, Buttgereit F. 2019; Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. Front Immunol. 10:1744. 44 McDonough AK, Curtis JR, Saag KG. 2008; The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 20(2):131–7. 45 Strehl C, Bijlsma JWJ, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TWJ, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, et al. 2016; Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 75(6):952–7. 46 Machold KP, Landewe R, Smolen JS, Stamm TA, van der Heijde DM, Verpoort KN, Brickmann K, Vazquez-Mellado J, Karateev DE, Breedveld FC, Emery P, Huizinga TW. 2010; The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 69(3):495–502. 47 2005. Trial registration: Primary prevention of rheumatoid arthritis - dexamethasone on autoantibody levels and arthritis development in patients with arthralgia [Internet]. 48 Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. 2010; Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 69(3):571–4. 49 van Aken J, Heimans L, Gillet-van Dongen H, Visser K, Ronday HK, Speyer I, Peeters AJ, Huizinga TW, Allaart CF. 2014; Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis. 73(2):396–400. 50 van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. 2007; Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56(5):1424–32. 51 van der Helm-van Mil AHM, Detert J, Cessie S le, Filer A, Bastian H, Burmester G, Huizinga T, Raza K. 2008; Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 58 8. 52 Burgers L, Allaart C, Huizinga T, Mil AHM van der H. 2017; Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis Rheumatol. 69. 53 Niemantsverdriet E, Dakkak YJ, Burgers LE, Bonte-Mineur F, Steup-Beekman GM, van der Kooij SM, Boom HD, Allaart CF, de Jong PHP, van der Helm-van Mil AHM. 2020; TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol. Trials. 21(1):862. 4
RkJQdWJsaXNoZXIy MTk4NDMw